Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 410

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

Yang, James Chih-Hsin, Shih, Jin-Yuan, Su, Wu-Chou, Hsia, Te-Chun, Tsai, Chun-Ming, Ou, Sai-Hong Ignatius, Yu, Chung-Jen, Chang, Gee-Chen, Ho, Ching-Liang, Sequist, Lecia V, Dudek, Arkadiusz Z, Shahidi, Mehdi, Cong, Xiuyu Julie, Lorence, Robert M, Yang, Pan-Chyr, Miller, Vincent A·2012·The Lancet Oncology
DOI 10.1016/s1470-2045(12)70086-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70086-4

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 19

  1. Janne, 2006, Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors, Clin Cancer Res, 12, 4416, 10.1158/1078-0432.CCR-06-0555 · DOI · Paper page
  2. Takano, 2008, EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan, J Clin Oncol, 26, 5589, 10.1200/JCO.2008.16.7254 · DOI
  3. Su, 2012, Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer, J Clin Oncol, 30, 433, 10.1200/JCO.2011.38.3224 · DOI · Paper page
  4. Li, 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, 27, 4702, 10.1038/onc.2008.109 · DOI · Paper page
  5. Regales, 2009, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer, J Clin Invest, 119, 3000
  6. Eskens, 2008, A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours, Br J Cancer, 98, 80, 10.1038/sj.bjc.6604108 · DOI · Paper page
  7. Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X · DOI · Paper page
  8. Lee, 2011, New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy, Lung Cancer, 73, 63, 10.1016/j.lungcan.2010.10.019 · doi:10.1016/j.lungcan.2010.10.019
  9. Mok, 2010, Living with imperfection, J Clin Oncol, 28, 191, 10.1200/JCO.2009.25.8574 · DOI
  10. Wu, 2008, First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer, Am J Respir Crit Care Med, 178, 847, 10.1164/rccm.200803-389OC · DOI
  11. Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, 28, 744, 10.1200/JCO.2009.24.3030 · DOI · Paper page
  12. Sequist, 2010, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer, J Clin Oncol, 28, 3076, 10.1200/JCO.2009.27.9414 · DOI · Paper page
  13. Won, 2011, Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations, J Clin Pathol, 64, 947, 10.1136/jclinpath-2011-200169 · DOI
  14. Jackman, 2006, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib, Clin Cancer Res, 12, 3908, 10.1158/1078-0432.CCR-06-0462 · DOI · Paper page
  15. Yang, 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, J Clin Oncol, 26, 2745, 10.1200/JCO.2007.15.6695 · DOI
  16. Janjigian Y, Groen H, Horn L. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. World Conference on Lung Cancer (WCLC) 2011; Amsterdam, Netherlands; July 3–7, 2011. Abstract O19.07.
  17. Neal, 2010, Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy, J Thorac Oncol, 5, 1855, 10.1097/JTO.0b013e3181f0bee0 · DOI
  18. Shao, 2010, Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer, Discov Med, 9, 538
  19. Ando, 2006, Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol, 24, 2549, 10.1200/JCO.2005.04.9866 · DOI · Paper page

Cited by

Metadata

Authors
Yang, J. C.-H., Shih, J.-Y., Su, W.-C., Hsia, T.-C., Tsai, C.-M., Ou, S.-H. I., Yu, C.-J., Chang, G.-C., Ho, C.-L., Sequist, L. V., Dudek, A. Z., Shahidi, M., Cong, X. J., Lorence, R. M., Yang, P.-C., & Miller, V. A.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2012-05
Volume
13
Issue
5
Pages
539-548
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(12)70086-4
OpenAlex
W2160336497
Cited by
410
References
13
FWCI
47.91
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.